Olema Cash Ratio from 2010 to 2025

OLMA Stock  USD 4.23  0.11  2.67%   
Olema Pharmaceuticals' Cash Ratio is decreasing over the years with very volatile fluctuation. Cash Ratio is expected to dwindle to 3.17. From 2010 to 2025 Olema Pharmaceuticals Cash Ratio quarterly data regression line had arithmetic mean of  16.12 and r-squared of  0.01. View All Fundamentals
 
Cash Ratio  
First Reported
2010-12-31
Previous Quarter
3.34019829
Current Value
3.17
Quarterly Volatility
17.42297442
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Olema Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Olema Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 13.3 M, Interest Income of 13.3 M or Depreciation And Amortization of 445.9 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.88. Olema financial statements analysis is a perfect complement when working with Olema Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Olema Pharmaceuticals Correlation against competitors.
For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.

Latest Olema Pharmaceuticals' Cash Ratio Growth Pattern

Below is the plot of the Cash Ratio of Olema Pharmaceuticals over the last few years. It is Olema Pharmaceuticals' Cash Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Olema Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Cash Ratio10 Years Trend
Very volatile
   Cash Ratio   
       Timeline  

Olema Cash Ratio Regression Statistics

Arithmetic Mean16.12
Geometric Mean8.06
Coefficient Of Variation108.11
Mean Deviation9.18
Median15.67
Standard Deviation17.42
Sample Variance303.56
Range73.789
R-Value(0.10)
Mean Square Error321.80
R-Squared0.01
Significance0.70
Slope(0.38)
Total Sum of Squares4,553

Olema Cash Ratio History

2024 3.34
2023 3.17
2022 1.43
2021 31.85
2020 73.84
2019 0.0493

About Olema Pharmaceuticals Financial Statements

Olema Pharmaceuticals stakeholders use historical fundamental indicators, such as Olema Pharmaceuticals' Cash Ratio, to determine how well the company is positioned to perform in the future. Although Olema Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Olema Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Olema Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Olema Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash Ratio 3.34  3.17 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Olema Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Olema Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Olema Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Olema Pharmaceuticals Stock:
Check out the analysis of Olema Pharmaceuticals Correlation against competitors.
For information on how to trade Olema Stock refer to our How to Trade Olema Stock guide.
You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Olema Pharmaceuticals. If investors know Olema will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Olema Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.20)
Return On Assets
(0.24)
Return On Equity
(0.39)
The market value of Olema Pharmaceuticals is measured differently than its book value, which is the value of Olema that is recorded on the company's balance sheet. Investors also form their own opinion of Olema Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Olema Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Olema Pharmaceuticals' market value can be influenced by many factors that don't directly affect Olema Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Olema Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Olema Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Olema Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.